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Introduction {#sec001}
============

**After kidney transplantation (KT), CD8**^**+**^ T cells have an important role in the development of the allograft rejection process, not only by direct invasion to allograft tissue, but also by recruitment and activation of other types of immune cells. \[[@pone.0234323.ref001]\] Indeed, markers for the activation of CD8^**+**^ T cells can be detected in the peripheral blood isolated from kidney-transplant recipients (KTRs); especially, CD8^**+**^ T cell subsets belonging to the terminally-differentiated effector-cell state are known to be involved in the process of allograft rejection. \[[@pone.0234323.ref002]--[@pone.0234323.ref005]\] In contrast, CD8^**+**^ T cell subtypes that display a naïve cell state can be involved in an "anti-rejection" process by regulation of effector T cells. \[[@pone.0234323.ref006]--[@pone.0234323.ref008]\] Therefore, it is possible that the dynamics of CD8^**+**^ T subsets in the peripheral blood can show a significant change according to "rejection" and "stable" state; hence it has been proposed that monitoring of CD8^**+**^ T cells subsets may be useful for detecting acute allograft rejection. \[[@pone.0234323.ref003], [@pone.0234323.ref009], [@pone.0234323.ref010]\]

In our previous studies, we investigated the role of CD8^+^ T cell subsets, especially CCR7^+^CD8^+^ T cells, the naïve T cell, in regard to the suppression of kidney allograft rejection. \[[@pone.0234323.ref011], [@pone.0234323.ref012]\] We found that this cell type has a suppressive effect on effector T cell subsets in *in vitro* study. Also, its proportion in peripheral blood was decreased in kidney-transplant recipients (KTRs) with T cell-mediated rejection (TCMR) compared to the normal-biopsy control (NC) groups. In contrast, effector T cell types, such as CD28^null^CD57^+^CD8^+^ T cells (immune senescent T cells), CCR7^-^CD45RA^+^CD8^+^ T cells (TEMRA), which are known to be involved in allograft rejection, were significantly increased in patients with acute rejection \[[@pone.0234323.ref003]--[@pone.0234323.ref005]\]. These results suggest that the phenotype analysis of CD8^+^ T cell subsets, especially the relative proportions between CCR7^+^CD8^+^ T cells and other effector CD8^+^ T cells, may be associated with the development of acute allograft rejection. In addition, peripheral blood transcripts apparently can reflect the systemic immune status or several critical clinical conditions. \[[@pone.0234323.ref013]--[@pone.0234323.ref016]\]

Based on the above background, we intended to investigate the dynamics of CD8^+^ T cell subsets, including CCR7^+^CD8^+^ T cells along with CD28^null^CD57^+^CD8^+^ T and CCR7^-^CD45RA^+^CD8^+^ T cells, in KTRs with TCMR compared to those with normal biopsy (NC) or long-term stable allograft survival (LTGS). We also investigated the association between CD8^+^ T cell subsets and molecular signatures obtained by means of transcript analysis using a microarray in those patients and attempted to infer changes in peripheral- blood transcripts with the change of T cell subsets during acute allograft rejection after KT.

Materials and methods {#sec002}
=====================

Patients and clinical information {#sec003}
---------------------------------

In an *ex vivo* study to compare CD8^+^ T cell subsets among clinical groups, peripheral-blood mononuclear-cell (PBMC) samples were chosen from the ARTKT-1 (assessment of immunologic risk and tolerance in kidney transplantation) study, a cross-sectional sample collection study of KTRs who had received kidney allograft biopsy or who had long-term allograft survival (LTGS) with stable allograft function (MDRD eGFR ≥ 50 mL/min/1.73 m^2^) over ten years at four different transplant centers (Kyoung Hee University Hospital at Gangdong, Kyung Hee University Hospital, Kyungpook National University Hospital, Seoul St. Mary\'s Hospital of Catholic University of Korea) from August 2013 to July 2015. \[[@pone.0234323.ref017]--[@pone.0234323.ref020]\] ARTKT-1 was used only to identify participants and access kidney tissue. Among the PBMC samples collected for the ARTKT-1 study, we used a total of 121 samples from 32 patients with normal biopsy without any evidence of rejection (NC group) and 50 patients who showed T cell-mediated rejection (TCMR) on allograft biopsy with Banff classification assessed by a single pathologist (TCMR group) \[[@pone.0234323.ref021]\] and 39 patients with LTGS for this study. We did not include patients who took any other solid organ transplantation in this study. The baseline characteristics of both groups are presented in [Table 1](#pone.0234323.t001){ref-type="table"}. All participants provided written informed consent in accordance with the Declaration of Helsinki. The study protocol was registered in the Clinical Research Information Service (CRIS Registration Number: KCT0001010), and was approved by the Institutional Review Board of each participating hospital. \[Seoul St. Mary's Hospital (KC13TNMI0701); Kyungpook National University Hospital (2013-10-010); Kyung Hee Neo Medical Center (IRB No. 2012-01-030)\].

10.1371/journal.pone.0234323.t001

###### Baseline characteristics of the kidney transplant recipients included in ex vivo study.

![](pone.0234323.t001){#pone.0234323.t001g}

                                             NC (n = 32)   TCMR (n = 50)   LTGS (n = 39)   *P*
  ------------------------------------------ ------------- --------------- --------------- ---------
  **Age (year)**                             41.5 ± 14.4   48.9 ± 11.6     56.0 ± 8.7      \<0.001
  **Male, n (%)**                            24 (75)       31 (62)         18 (46)         0.045
  **Post-transplant month**                  6.6 ± 1.4     18.0 ± 20.0     204.5 ± 84.8    \<0.001
  **MDRD eGFR (mL/min/1.73 m**^**2**^**)**   69.6 ± 37.8   32.5 ± 15.4     69.5 ± 16.5     \<0.001
  **HLA mismatch number**                    3.9 ± 1.5     3.2 ± 1.7       2.2 ± 1.3       \<0.001
  **ABO incompatible KT, n (%)**             8 (25)        13 (26)         0 (0)           \<0.001
  **Previous TCMR, n (%)**                   1 (3)         24 (48)         0 (0)           \<0.001
  **Pretransplant DSA, n (%)**               5 (16)        10 (20)         1 (3)           \<0.001
  **Re-transplant, n (%)**                   5 (16)        5 (10)          1 (3)           0.156
  **Indication for biopsy**                                                                
  Protocol biopsy, n (%)                     3 (9)         7 (14)          N/A             \<0.001
  Indicated biopsy, n (%)                    29 (91)       43 (86)         N/A             
  **Induction IS**                                                                         
  Basiliximab, n (%)                         30 (94)       43 (86)         34 (87)         0.540
  Anti-thymocyte globulin, n (%)             2 (6)         7 (14)          5 (13)          
  **Maintenance IS**                                                                       
  Tacrolimus, n (%)                          31 (97)       37 (74)         10 (26)         \<0.001
  Cyclosporin, n (%)                         0 (0)         10 (20)         18 (46)         \<0.001
  mTOR inhibitor, n (%)                      2 (6)         2 (4)           3 (8)           0.754
  Mycophenolate Mofetil, n (%)               29 (91)       40 (80)         10 (26)         \<0.001
  Steroid, n (%)                             31 (97)       42 (84)         20 (51)         \<0.001
  Azathioprine, n (%)                        0 (0)         0 (0)           4 (10.3)        0.013
  **Donor information**                                                                    
  Deceased donor, n (%)                      7 (22)        19 (38)         6 (15)          0.014
  Donor age                                  48.6 ± 7.8    47.1 ± 12.2     35.5 ± 11.9     \<0.001
  Donor gender (male, n (%))                 15 (47)       29 (58)         21 (54)         0.615

DSA, donor specific antibody; eGFR, estimated glomerular filtration rate; IS, immune suppression; KT, kidney transplantation; LTGS, long term graft survival; MDRD, Modification of diet in renal disease; NC, Normal biopsy control; TCMR, T cell mediated rejection

Flowcytometric analysis of peripheral-blood CD8^+^ T cells isolated from kidney-transplant recipients {#sec004}
-----------------------------------------------------------------------------------------------------

From 121 KTRs, PBMCs (1 x 10^6^ cells/mL) were prepared from heparinized blood by Ficoll--Hypaque (GE Healthcare) density-gradient centrifugation. Cells were stored frozen at each center within 1 hour after the sampling of peripheral blood. They transported to our center for flowcytometric analysis. Cells were cultured as described previously \[[@pone.0234323.ref012], [@pone.0234323.ref022]\]. In brief, a cell suspension of 1 x 10^6^ cells/mL was prepared in RPMI1640 medium supplemented with 10% FCS, 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mM L-glutamine. The cells were surface-stained with different combinations of the following monoclonal antibodies: CD8--APC (SK1, IgG1,κ; BD), CCR7-strepavidin (3D12, IgG2a, κ), CD45RA--FITC (HI100, IgG2b, k; BD), CD28-PE (CD28.2, IgG1,κ, eBioscience) and CD57-FITC (TB01, IgM, eBioscience). Appropriate isotype controls were used for gating purposes. Cells were analyzed using a FACS Calibur flow cytometer (BD Biosciences). We analyzed the data using FlowJo software (Tree Star).

Relationships between transcriptome expression and T cell subsets {#sec005}
-----------------------------------------------------------------

Previously, we did both microarray and flowcytometry analysis in 153 KTRs belonging to ARTKT-1 study. \[[@pone.0234323.ref018]\] For this study, we used microarray and flowcytometry data of 108 KTRs in whom the data for CCR7^+^CD8^+^ T, CCR7^-^CD45RA^+^CD8^+^ T, and CD28^null^CD57^+^CD8^+^ T cells were available. The microarray analysis using RNA isolated from peripheral blood from KTRs was described previously. \[[@pone.0234323.ref018]\] Briefly, peripheral blood was collected in 2.5 mL PAXgene^TM^ Blood RNA Tubes (PreAnalytiX, Qiagen) and total RNA was extracted from PAXgene samples using Paxgene Blood miRNA Kit (PreAnalytiX, Qiagen) according to manufacturer's protocol. We measured quantity and quality of total RNA using Agilent's 2100 Bioanalyzer. We used the universal human reference RNA (Agilent Technology, USA) as control for two-color microarray-based gene-expression analysis and synthesized the target cRNA probes and hybridization using Agilent's Low RNA Input Linear Amplification kit (Agilent Technology, USA) according to the manufacturer's instructions. The hybridized images were scanned using Agilent's DNA microarray scanner and quantified with Feature Extraction Software (Agilent Technology, Palo Alto, CA). All data normalization and selection of fold-changed genes were done using GeneSpringGX 7.3 (Agilent Technology, USA). The averages of normalized ratios were calculated by dividing the average of normalized signal channel intensity by the average of normalized control channel intensity.

We identified significant changes in gene expression associated with cell types using the SAM (Significance Analysis of Microarray) R package \[[@pone.0234323.ref023]\]. Briefly, expression data in 101 samples matched to cell-phenotype data were normalized by rescaling mean 0 and standard deviation 1, and then SAM analysis was used for cell-type expressivity as a quantitative response variable. The false discovery rates were obtained from 1,000 permutations. We discovered significantly differently expressed genes (FDR \< 0.05) for each of the cell types.

Microarray analysis using isolated CCR7^+^ CD8^+^ T or CCR7^-^ CD8^+^ T cells from healthy volunteers {#sec006}
-----------------------------------------------------------------------------------------------------

### Isolation of CCR7^+^ CD8^+^ T or CCR7^-^ CD8^+^ T cells and extraction of RNA {#sec007}

From three healthy volunteers, PBMCs (1 x 10^**6**^ cells/mL) were prepared from heparinized blood (10cc) by Ficoll--Hypaque (GE Healthcare) density-gradient centrifugation. To expand CCR7^**+**^CD8^**+**^ T cells, isolated PBMCs were stimulated using anti-CD3, IL-15, IL-2, and retinoic acid. Cells were cultured as described previously. \[[@pone.0234323.ref011]\] We pooled cells for microarray as opposed to single cell RNA sequencing. CCR7^**+**^ CD8^**+**^ T cells were purified by CD8--APC (SK1, IgG1,κ; BD) and CCR7-strepavidin (3D12, IgG2a, κ). The cells were sorted using an FACS Aria device (Becton Dickinson) or a MoFlo cell sorter (Beckman Coulter) to isolate CCR7^**+**^ CD8^**+**^ and CCR7^**-**^ CD8^**+**^ T cells. We extracted mRNA from CCR7^**+**^CD8^**+**^ and CCR7^**-**^ CD8^**+**^ T cells using the ReliaPrep™ RNA Miniprep Systems (Promega Corporation, Madison, WI, USA), according to the manufacturer's instructions. RNA purity and integrity were evaluated by ND-1000 Spectrophotometer (NanoDrop, Wilmington, DE, USA).

### Affymetrix whole transcript expression array method {#sec008}

We carried out the Affymetrix Whole Transcript Expression array process according to the manufacturer\'s protocol (GeneChip WT Pico Reagent Kit). We synthesized cDNA using the GeneChip WT Pico Amplification kit as described by the manufacturer. The sense cDNA was fragmented and biotin-labeled with TdT (terminal deoxynucleotidyl transferase) using the GeneChip WT Terminal labeling kit. Approximately 5.5 μg of labeled DNA target was hybridized to the Affymetrix GeneChip Human 2.0 ST Array at 45°C for 16 hours. Hybridized arrays were washed and stained on a GeneChip Fluidics Station 450 and scanned on a GCS3000 Scanner (Affymetrix). Signal values were computed using the Affymetrix® GeneChip™ Command Console software.

Raw data preparation and statistical analysis {#sec009}
---------------------------------------------

Statistical analysis was done by using SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA). Values between groups were compared using one-way analysis of variance. For categorical variables, chi-square frequency analysis was used. The results are presented as mean ± standard deviation (SD). *P* values \< 0.05 were considered significant. For microarray analysis, raw data were extracted automatically in the Affymetrix data-extraction protocol using software provided by Affymetrix GeneChip® Command Console® Software (AGCC). After we imported CEL files, we summarized and normalized the data with the robust multi-average (RMA) method implemented in Affymetrix® Expression Console™ Software (EC). We exported the results with gene-level RMA analysis and carried out differently expressed gene (DEG) analysis. Statistical significance of the expression data was assessed using fold change and an LPE test in which the null hypothesis was that no difference exists between groups. The false discovery rate (FDR) was controlled by adjusting the *p* value using the Benjamini-Hochberg algorithm. For a DEG set, we did hierarchical cluster analysis using complete linkage and Euclidean distance as a measure of similarity. All data analysis and visualization of differently expressed genes was done using R 3.1.2 ([www.r-project.org](http://www.r-project.org/)). For the analysis of the relationships between transcriptome expression and T cell subsets, a score for each gene of a statistically significant change in gene expression relative to cell type was established by *t* tests, and the "*q* value" for each gene was the lowest false discovery rate (FDR). Significant genes were selected by high score and *q* \< 0.05.

Results {#sec010}
=======

Ex vivo analysis of CD8^+^ T cell subset in KTRs {#sec011}
------------------------------------------------

[Fig 1A](#pone.0234323.g001){ref-type="fig"} shows representative flow cytometric data for lymphocytes, CD8^+^ T, CCR7^+^CD45RA^+^CD8^+^ T, CCR7^+^CD45RA^-^CD8^+^ T, CCR7^+^CD8^+^T, CCR7^−^CD45RA^-^CD8^+^ T, CCR7^−^CD45RA^+^CD8^+^T and CD28^null^CD57^+^CD8^+^T cells in KTRs. The percentage of lymphocytes was significantly decreased in the TCMR group in comparison with the NC group (p \< 0.01) and LTGS group (*p* \< 0.05) ([Fig 1B](#pone.0234323.g001){ref-type="fig"}). In contrast, the percentage of CD8^+^ out of lymphocytes was significantly increased in the TCMR group in comparison with the NC group or LTGS group (*p* \< 0.01 for each) ([Fig 1C](#pone.0234323.g001){ref-type="fig"}). The percentage of CCR7^+^CD45RA^+^CD8^+^ T cells and CCR7^+^CD45RA^-^CD8^+^ T cells was significantly decreased in the TCMR group in comparison with the NC group (*p* \< 0.01) ([Fig 1D and 1E](#pone.0234323.g001){ref-type="fig"}). Therefore, the percentage of CCR7^+^CD8^+^ T cells was also significantly decreased in the TCMR group in comparison with the NC group (p \< 0.01) and LTGS group (*p* \< 0.001) ([Fig 1F](#pone.0234323.g001){ref-type="fig"}). In contrast, the proportion of CCR7^−^CD45RA^+^CD8^+^ T and CD28^null^CD57^+^CD8^+^ T cells were significantly higher in the TCMR group than in the NC group (*p* \< 0.05) or LTGS group, respectively (*p* \< 0.05 for all) ([Fig 1H and 1I](#pone.0234323.g001){ref-type="fig"}).

![Comparison of CD8^+^ T cell subset among NC, TCMR and LTGS groups.\
(A) PBMCs were stained with anti-CD8--APC, anti-CCR7 strepavidin, anti-CD45RA FITC, anti-CD28-PE and anti-CD57-FITC antibodies. CD8^**+**^ T cells were gated for further analysis. (B-I) Proportion (%) of (B) Lymphocytes, (C) CD8^**+**^ T cells/lymphocytes, (D) CCR7^**+**^CD45RA^**+**^CD8^**+**^ T cells, (E) CCR7^**+**^CD45RA^**-**^CD8^**+**^ T cells, (F) CCR7^**+**^CD8^**+**^ T cells, (G) CCR7^**-**^CD45RA^**-**^CD8^**+**^ T cells, (H) CCR7^**-**^CD45RA^**+**^CD8^**+**^ T cells, (I) CD28^null^ CD57^+^CD8^**+**^ T cells in each patient group. \**p* \< 0.05 vs. NC, ^†^*p* \< 0.05 vs. LTGS. Abbreviations; LTGS, long-term graft survival; NC, Normal control; TCMR, T cell mediated rejection.](pone.0234323.g001){#pone.0234323.g001}

Association between CCR7^+^CD8^+^ T cells and other effector T cells in KTRs and in vitro condition {#sec012}
---------------------------------------------------------------------------------------------------

In the *ex vivo* study in KTRs, the proportion of CCR7^+^CD8^+^ T cells showed a significant negative correlation with CD28^null^CD57^+^CD8^+^ T (*p* \< 0.001, *R*^2^ = 0.38), and CCR7^−^CD45RA^+^CD8^+^ (*p* \< 0.001, *R*^2^ = 0.51) ([Fig 2A and 2B](#pone.0234323.g002){ref-type="fig"}). Therefore, when we compared the log transformation value of the ratio between two types of effector T cells (CD28^null^CD57^+^CD8^+^ T or CCR7^−^CD45RA^+^CD8^+^ T) and CCR7^+^CD8^+^ T cells, it was significantly lower in the TCMR group than in the NC or LTGS group (*p* \< 0.05 for both)([Fig 2C and 2D](#pone.0234323.g002){ref-type="fig"})

![Association between CCR7^+^/CD8^+^ T cells and effector T cell subsets in an *in vitro* and in an *ex vivo study*.\
PBMCs were stained with anti-CD8--APC, anti-CCR7 strepavidin, anti-CD45RA FITC, anti-CD28-PE and anti-CD57-FITC antibodies. Lymphocytes were gated for further analysis. **(A)** The proportion (%) of CCR7^**+**^CD8^**+**^ T cells showed a significant negative correlation with the proportion (%) of CD28^null^ CD57^+^CD8^**+**^ T cells (*p* \< 0.001, *r*^2^ = 0.38). **(B)** The proportion (%) of CCR7^**+**^CD8^**+**^ T cells showed a significant negative correlation with the proportion (%) of CCR7^**-**^CD45RA^**+**^CD8^**+**^ T cells (*p* \< 0.001, r^2^ = 0.51). **(C)** Comparison of log (CCR7^+^CD8^+^ T cells / CD28^null^CD57^+^CD8^+^ T cells) in each patient group. **(D)** Comparison of log (CCR7^+^CD8^+^ T / CCR7^**-**^CD45RA^**+**^CD8^**+**^ T cells) in each patient group \* *p* \< 0.05 vs. NC, ^†^ *p* \< 0.05 vs. LTGS. In an *in vitro* study on CCR7^+^CD8^+^ T cells induction protocol, PBMCs were collected from healthy individuals, plated at 2 × 10^5^ cells per well, and stimulated with anti-CD3 Abs (0.1 μg/ml), recombinant IL-15 (20 ng/ml), IL-2 (20 ng/ml), and retinoic acid (1 μg/ml). On day 3, cells were harvested, stained with antibodies specific to CD8, CCR7, CD45RA, CD28 and CD57, and analyzed by flow cytometry. (**E**) Proportion (%) of CCR7^**+**^CD8^**+**^ T cells, (F) Proportion (%) of CD28^null^CD57^+^CD8^**+**^ T cells, **(G)** Proportion (%) of CCR7^**-**^CD45RA^**+**^CD8^**+**^ T cells on CCR7^+^CD8^+^ T cells induction protocol. Bars represent the median with range. \**p* \< 0.05 vs. CCR7^+^CD8^+^ T cell condition. Abbreviations; LTGS, long-term graft survival; NC, Normal control; TCMR, T cell mediated rejection.](pone.0234323.g002){#pone.0234323.g002}

In an *in vitro* study on CCR7^+^CD8^+^ T cells induction protocol using PBMCs isolated from healthy volunteers, the proportion of CCR7^+^CD8^+^ T cells was significantly higher on the CCR7^+^CD8^+^ induction protocol than Nil (*p* \< 0.001) ([Fig 2C](#pone.0234323.g002){ref-type="fig"}). In contrast, the CCR7^+^CD8^+^ T cells induction protocol significantly reduced the proportion of CD28^null^CD57^+^CD8^+^ (*p* \< 0.01) and CCR7^−^CD45RA^+^CD8^+^ in contrast with Nil ([Fig 2E--2G](#pone.0234323.g002){ref-type="fig"}).

Association analysis between peripheral transcriptome and ex vivo CD8^+^ T cell subsets {#sec013}
---------------------------------------------------------------------------------------

We investigated significant changes of the gene expression in peripheral blood associated with CCR7^+^CD8^+^ T, CCR7^-^CD45RA^+^CD8^+^ T, and CD28^null^CD57^+^CD8^+^ T cells in an *ex vivo* study. We identified 13 up-regulated genes but no down-regulated genes in KTRs with the high proportion of CCR7^+^CD8^+^ T cells **([S1 Table](#pone.0234323.s002){ref-type="supplementary-material"}).** We also identified eight increased and three decreased genes in KTRs along with the change of proportion of CCR7^-^CD45RA^+^CD8^+^ T and found 124 up-regulated and 19 down-regulated genes in those along with the change of CD28^null^CD57^+^CD8^+^ T cells **([S2](#pone.0234323.s003){ref-type="supplementary-material"} and [S3](#pone.0234323.s004){ref-type="supplementary-material"} Tables).**

Microarray analysis of RNA from isolated CCR7^+^CD8^+^ T and CCR7^-^CD8^+^ T cells in healthy volunteers {#sec014}
--------------------------------------------------------------------------------------------------------

We did microarray analysis on CCR7^+^CD8^+^ T cells compared with CCR7^-^CD8^+^ T isolated and induced using the PBMC from the same donors (*n* = 3) ([Fig 3A](#pone.0234323.g003){ref-type="fig"}) and identified 992 differently expressed genes. Moreover, comparison of the leading-edge gene set (the core set of genes that account for this enrichment) from each T cell population distinguished a core of 450 up-regulated (see [S4 Table](#pone.0234323.s005){ref-type="supplementary-material"}) and 542 down-regulated (see [S5 Table](#pone.0234323.s006){ref-type="supplementary-material"}) genes that were commonly enriched in all CCR7^+^-expressing CD8^+^ T cells and therefore define the CCR7^+^CD8^+^-associated transcriptional signature. Genes whose expression levels were higher than the assumed threshold (up-regulated *\>* 1.5-fold and down-regulated *\<* 1.5-fold) were visualized using the scatter plot method ([Fig 3B](#pone.0234323.g003){ref-type="fig"}).

![Gene expression in CCR7^+^CD8^+^ T cells and CCR7^-^CD8^+^ T cells using microarray.\
(A) Hierarchical clustering of gene expression in CCR7^+^CD8^+^ T cells and CCR7^-^CD8^+^ T cells. Heatmap is showing 992 significantly (*p \<* 0.05) differently expressed transcripts between CCR7^+^CD8^+^ T cells and CCR7^-^CD8^+^ T cells in three donors. The 992 genes were selected for this analysis by the criteria described in Materials and Methods. Expression levels are normalized for each gene and shown by color, with yellow representing high expression and blue representing low expression. (B) Scatter plot of expression level between CCR7^+^CD8^+^ T cells and CCR7^-^CD8^+^ T cells. (C) The overlap between the genes expressed on *ex vivo* CCR7^-^CD45^+^CD8^+^ T cells matched with in vitro CCR7^-^CD8^+^ T cell data and CD28^null^CD57^+^CD8^+^ T cells related blood transcripts that matched with *in vitro* CCR7^-^CD8^+^ T cell data.](pone.0234323.g003){#pone.0234323.g003}

In addition, we investigated the relationships between the genes expressed along CD8^+^ T cell subsets on *ex vivo* and 992 genes expressed on *in vitro* CCR7^+^CD8^+^ T cells. Out of the 13 increasingly changed genes along with the *ex vivo* CCR7^+^CD8^+^ T cells, six genes were included in the up-regulated genes on *in vitro* CCR7^+^CD8^+^ T cells ([Table 2](#pone.0234323.t002){ref-type="table"}). Out of the eight up-regulated genes along with the *ex vivo* CCR7^-^CD45^+^CD8^+^ T cells ([S2 Table](#pone.0234323.s003){ref-type="supplementary-material"}), five genes were included in the down-expressed genes on *in vitro* CCR7^+^CD8^+^ T cells ([Table 3](#pone.0234323.t003){ref-type="table"}). In addition, out of three down-regulated genes along with the *ex vivo* CCR7^-^CD45^+^CD8^+^ T cells ([S2 Table](#pone.0234323.s003){ref-type="supplementary-material"}), two genes were included in the up-expressed genes on *in vitro* CCR7^+^CD8^+^ T cells ([Table 3](#pone.0234323.t003){ref-type="table"}). Also, 25 out of 124 up-regulated genes and 10 out of 19 down-regulated genes along with *ex vivo* CD28^null^CD57^+^CD8^+^ T cells ([S3 Table](#pone.0234323.s004){ref-type="supplementary-material"}) were included in the down-regulated or up-regulated genes on *in vitro* CCR7^+^CD8^+^ T cells, respectively, as shown in [Table 4](#pone.0234323.t004){ref-type="table"}. The genes expressed on *ex vivo* CCR7^-^CD45^+^CD8^+^ T cells were correlated with those on *ex vivo* CD28^null^CD57^+^CD8^+^ T cells, except for CA6 ([Fig 3C](#pone.0234323.g003){ref-type="fig"}). These results showed that CCR7^+^CD8^+^ T cells are negatively correlated with CCR7^-^CD45RA^+^CD8^+^ T and CD28^null^CD57^+^CD8^+^ T cells in both cell phenotype and molecular signature.

10.1371/journal.pone.0234323.t002

###### CCR7^+^CD8^+^ T cells related blood transcripts that matched with in vitro CCR7^+^CD8^+^ T cell data.

![](pone.0234323.t002){#pone.0234323.t002g}

  Gene Symbol   Score (d)   q-value (%)
  ------------- ----------- -------------
  CA6           3.957       0
  EDAR          3.674       0
  NOG           3.585       0
  GCNT4         3.442       0
  LEF1          3.380       0
  LRRN3         3.147       4.136

10.1371/journal.pone.0234323.t003

###### CCR7^-^CD45RA^+^CD8^+^ T cells related blood transcripts that matched with in vitro CCR7^+^CD8^+^ T cell data.

![](pone.0234323.t003){#pone.0234323.t003g}

  Gene Symbol   Score (d)   q-value (%)
  ------------- ----------- -------------
  ITPRIPL1      4.373       0
  B3GAT1        4.258       0
  PPP2R2B       4.058       0
  KLRD1         3.826       0
  PLEKHF1       3.748       0
  CA6           -3.654      0
  GAL3ST4       -3.552      0

10.1371/journal.pone.0234323.t004

###### CD28^null^CD57^+^CD8^+^ T cells related blood transcripts that matched with in vitro CCR7^+^CD8^+^ T cell data.

![](pone.0234323.t004){#pone.0234323.t004g}

  Gene Symbol   Score (d)   q-value (%)
  ------------- ----------- -------------
  ITPRIPL1      4.672       0
  MATK          4.320       0
  B3GAT1        4.216       0
  CLIC3         4.075       0
  ABI3          3.660       0
  NBEAL2        3.647       0
  CACNA2D2      3.480       2.46
  PPP2R2B       3.476       2.46
  C1orf21       3.439       2.46
  KLRD1         3.419       2.46
  C12orf75      3.332       2.46
  PDGFRB        3.307       2.46
  LIMK1         3.295       2.46
  SMAD7         3.273       2.46
  ITGAL         3.270       2.46
  MB21D1        3.167       2.46
  CEP78         3.133       2.46
  TFDP2         3.108       2.46
  CST7          3.106       2.46
  TM4SF19       3.088       2.46
  GNLY          3.055       2.46
  PLEKHF1       3.036       2.46
  SEMA7A        3.028       2.46
  MYO1G         3.004       2.46
  MT1E          2.983       2.46
  PLAG1         -4.151      0
  GAL3ST4       -4.070      0
  FAM134B       -3.679      2.46
  LEF1          -3.543      2.46
  PKIA          -3.420      2.46
  NOG           -3.418      2.46
  FAM153A       -3.412      2.46
  FOXO1         -3.403      2.46
  PDK1          -3.341      2.46
  MEST          -3.324      2.46

Receiver Operating Characteristic (ROC) curve analysis to evaluate the ability of the ratios between CD8 T cell subsets to predict AR {#sec015}
-------------------------------------------------------------------------------------------------------------------------------------

We evaluated the diagnostic power of CCR7^+^CD8^+^T, CCR7^−^CD45RA^+^CD8^+^T, CD28^null^CD57^+^CD8^+^ T cells, the ratio between CCR7^+^CD8^+^T and CCR7^−^CD45RA^+^CD8^+^T and between CCR7^+^CD8^+^T and CD28^null^CD57^+^CD8^+^ T cells to distinguish the acute rejection state from normal biopsy or long-term stable condition using the AUC, which was found via ROC curve analysis ([Fig 4](#pone.0234323.g004){ref-type="fig"}). The AUCs of CCR7^+^CD8^+^T, CD28^null^CD57^+^CD8^+^ T cells, and CCR7^−^CD45RA^+^CD8^+^T were 0.785, 0.728, and 0.675 respectively. The AUC value was increased to 0.768 and 0.800 when we used the ratio between CCR7^+^CD8^+^T and CCR7^−^CD45RA^+^CD8^+^T or between CCR7^+^CD8^+^T and CD28^null^CD57^+^CD8^+^ T cells respectively. After the integration of both ratios, they did not increase from the AUCs of the ratio between CCR7^+^CD8^+^T and CD28^null^CD57^+^CD8^+^ T cells.

![Receiver operating characteristics curves to evaluate the discriminative power of the combination of CD8^+^ T cell subsets in distinguishing TCMR from the NC or LTGS groups.\
**(A)** CCR7^+^CD8^+^ T (**B**) CD57^+^CD28^null^CD8^+^ T **(C)** CD45RA^+^CCR7^-^CD8^+^ T **(D)** The ratio between CCR7^+^CD8^+^ T vs CD28^null^CD57^+^CD8^+^ T **(E)** The ratio between CCR7^+^CD8^+^ T vs. CD45RA^+^CCR7^-^CD8^+^ T **(F)** Combination of the ratio between CCR7^+^CD8^+^ T vs CD28^null^CD57^+^CD8^+^ T and the ratio between CCR7^+^CD8^+^ T vs CD45RA^+^CCR7^-^CD8^+^ T. Abbreviations; LTGS, long-term graft survival; NC, Normal control; TCMR, T cell mediated rejection.](pone.0234323.g004){#pone.0234323.g004}

Discussion {#sec016}
==========

In this study, we analyzed various CD8^+^ T cell subsets using flow cytometry and a microarray method to see the relationship between regulatory and effector CD8^+^ T cell subsets in kidney transplant recipients with acute rejection. Finally, we found that CCR7^+^CD8^+^ T showed a negative relationship to inflammatory subsets (CD28^null^CD57^+^CD8^+^ T and CCR7^-^CD45RA^+^CD8^+^ T cells), not only in the cell-proportion results by flow cytometry but also in the transcriptomic expression by microarray. Therefore, our results showed that combined analysis of the CD8^+^ T cell subset can be a useful tool for detecting the development of acute rejection.

First, we tried to compare the proportion of each CD8+ T cell subset in the different clinical groups, NC, AR, and LTGS. Previously, we found that CD8^+^CCR7^+^ T cells showed an immune-regulatory function on the other effector T cells; that function showed a negative relationship to effector CD8+ T cells involved in the development of acute rejection in a few patients \[[@pone.0234323.ref011]\]. In this study, we used a larger patient group and found the decrease of CD8^+^CCR7^+^ T cells and increase of effector CD8^+^ T cells, such as CD28^null^CD57^+^CD8^+^ T and CCR7^-^CD45RA^+^CD8^+^ T cells in KTRs with AR in comparison with those in the NC or LTGS groups in the *ex vivo* flowcytometric analysis using PBMCs isolated from KTRs. In addition, we found the negative relationship between CCR7^+^CD8^+^ T cells and other effector T cells, as our previous study \[[@pone.0234323.ref011]\]. We tried to confirm those relationships in an *in vitro* study. In this experiment, we used a previously established protocol, including anti-CD3, IL-15, IL-2, and retinoic acid, for the induction of CCR7^+^CD8^+^ T cells \[[@pone.0234323.ref024], [@pone.0234323.ref025]\] and found that with the increase of CCR7^+^CD8^+^ T cells, the proportion of CD28^null^CD57^+^CD8^+^ T and CCR7^-^CD45RA^+^CD8^+^ T cells showed a decrease in CCR7^+^CD8^+^ T cell induction condition in comparison with Nil condition.

Next, we did microarray analysis to profile genes in peripheral blood in KTRs using Agilent's Human Oligo Microarray 60K (V2) and identified significant genes changed along with the cell proportion of CD8^+^ T cell subsets by the *ex vivo* flowcytometric analysis. The changes in T cell subsets developed associated with acute rejection in KTRs have been frequently investigated, including in our own works \[[@pone.0234323.ref005], [@pone.0234323.ref022], [@pone.0234323.ref026]\]. In contrast, there has been little research on the molecular signatures representing the changes in T cell subsets. Recently, the new development of an assay for an RNA transcript enabled the analysis of the molecular signature of the immune cells specific to the disease status in KTRs \[[@pone.0234323.ref027]--[@pone.0234323.ref029]\]. In this study, candidate molecular signatures of rejection-specific T cell subsets were identified in peripheral-blood microarray analysis, and these molecular signatures were verified by *in vitro* analysis.

Interestingly, a significant portion of genes identified as related to the change of CCR7^+^CD8^+^ T, CCR7^-^CD45^+^CD8^+^ T, and CD28^null^CD57^+^CD8^+^ T cells *ex vivo* were matched with CCR7^+^CD8^+^ T cells in *in vitro* transcript analysis (6/13 genes in CCR7^+^CD8^+^ T, 7/11 in CCR7^-^CD45^+^CD8^+^ T, and 35/143 in CD28^null^CD57^+^CD8^+^ T cells) Moreover, the negative correlation between the CCR7^+^CD8^+^ T and effector T cell subset and also a positive correlation between CCR7^-^CD45^+^CD8^+^ T and CD28^null^CD57^+^CD8^+^ T observed in phenotype analysis by flow cytometry was also maintained in the expression of these transcripts (Figs [2](#pone.0234323.g002){ref-type="fig"} and [3](#pone.0234323.g003){ref-type="fig"} and [S1 Fig](#pone.0234323.s001){ref-type="supplementary-material"}). All of the above findings suggest the reciprocal relationship between CCR7^+^CD8^+^ T cells and effector T cells subsets; hence they may suggest that the ratio between CCR7^+^CD8^+^ T cells and effector T cells subset can be significantly associated with development of TCMR rather than single-cell analysis.

Therefore, we appraised the significance of the ratio between CCR7^+^CD8^+^ T cells and other effector CD8^+^ T cells as well as single-cell results for the prediction of acute rejection. We found that the ratio between cell types showed better prediction for AR than did single-cell analysis, and the ratio between CCR7^+^CD8^+^ T and CD28^null^CD57^+^CD8^+^ T showed the highest value for AR prediction. Unfortunately, the integration of the two ratio markers did not increase the predictive value over that of the ratio between CCR7^+^CD8^+^ T and CD28^null^CD57^+^CD8^+^ T itself. Indeed, CCR7^−^CD45RA^+^CD8^+^ T and CD28^null^CD57^+^CD8^+^ T showed a significant correlation with each other; hence many of them can overlap ([S1 Fig](#pone.0234323.s001){ref-type="supplementary-material"}). That\'s why integration of the two ratios did not increase the predictive value.

Our study has some limitations. We analyzed samples taken from a cross-sectional cohort; hence we did not investigate the dynamic changing pattern of each cell type. It will be necessary to observe the change of each cell type in a prospective cohort. Second, it was not validated in another cohort. Third, because of the inherent limitations of the entire transcriptome assay, too few transcripts for each rejection-specific T cell subset were identified. If it can be supplemented by means of a single-cell assay in the future, development of rejection-specific transcriptomic markers using peripheral blood will become possible. \[[@pone.0234323.ref030]--[@pone.0234323.ref032]\] In addition, three groups showed significant heterogeneity in terms of clinical characteristics. For example, patient age, type of immune suppressant, different post-transplant duration can impact on the result. Especially, induction immunosuppression, high-dose initial maintenance immunosuppression, and ABO desensitization may have contributed to observed findings in patients with less than 6 months from KT. Lastly, we did not show donor-specificity of T cell responses, which can limit the novelty of this study.

In conclusion, we found the relative decrease of CD8^+^ T cells with a regulatory function compared to effector CD8^+^ T cell subsets was the important phenomenon that can be detected in TCMR in comparison with NC or LTGS. We demonstrated this phenomenon in the phenotype analysis using flow cytometry, and also found that the distribution of CD8^+^ T cell subsets are correlated with molecular signatures by microarray transcript analysis. These findings suggest that combined monitoring of regulatory and effector CD8^+^ T cells subsets can be used as a surrogate marker of TCMR in KTRs.

Supporting information {#sec017}
======================

###### Association between CCR7-CD45RA^+^CD8^+^ T cells and CD28nullCD57^+^CD8^+^ T cells.

The proportion (%) of CCR7^-^CD45RA^+^CD8^+^ T cells showed a significant correlation with the proportion (%) of CD28^null^CD57^+^CD8^+^ T cells (*p* \< 0.001, *r*^2^ = 0.44).

(PDF)

###### 

Click here for additional data file.

###### Significantly changed genes along *ex vivo* CCR7^+^CD8^+^T cells.

(PDF)

###### 

Click here for additional data file.

###### Significantly changed genes along *ex vivo* CCR7-CD45RA^+^CD8^+^T cells.

(PDF)

###### 

Click here for additional data file.

###### Significantly changed genes along *ex vivo* CD28nullCD57^+^CD8^+^T cells.

(PDF)

###### 

Click here for additional data file.

###### Up-regulated genes in CCR7^+^CD8^+^ T cells compared with CCR7-CD8^+^ T cells.

(PDF)

###### 

Click here for additional data file.

###### Down-regulated genes in CCR7^+^CD8^+^ T cells compared with CCR7-CD8^+^ T cells.

(PDF)

###### 

Click here for additional data file.

AR

:   acute rejection

BPAR

:   biopsy-proven acute rejection

FDR

:   False discovery rate

KT

:   kidney transplantation

KTR

:   kidney-transplant recipient

LTGS

:   long-term graft survival

NC

:   normal biopsy control

PBMC

:   peripheral blood mononuclear cells

TCMR

:   T cell-mediated rejection
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The manuscript is of potential interest to the renal transplant community. However, it is not acceptable for publication in its current form. There is a considerable heterogeneity of the study groups with respect to important baseline characteristics, that may have confounded the presented findings and preclude conclusions. In order to decide if this is the case I would ask you to provide more detailed both methodology and results description:

Please provide information on clinical characteristics with respect to: retansplantation, other solid organ transplantation, previous TCMR, presensitization.Please provide a comment on the significant differences between the 3 study groupsWhat was the selection process of samples ie n=32 normals + n=50 TCMR + n=39 LTGS = 121 total from the banked biosamples of the ARTKT-1 study?What were the indications for the n=91 biopsies in the normal biopsy control group in table 1?Please confirm that ARTKT-1 was used only to identify participants and access kidney tissue.  Participants were then approached for their peripheral blood. (Methods describes flow cytometry on blood within a few hours of collection).  If this is so, what is the time interval between deposition of biosamples in ARTKT-1 and the sampling of the peripheral blood?The number of participants/analyzed samples differs for various analyses - Please account for the reduced sample set, including which groups were reduced by how much and why.

There are also other issues, which are described in detail by the Reviewers.

We would appreciate receiving your revised manuscript by Apr 02 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Justyna Gołębiewska

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Research pursues one of the universal aims of kidney transplantation: cells in the peripheral blood tell us the pathobiological processes in the allograft.

Strengths of the research

• access to samples -- over 10 years clinical follow up, sound control groups, access to the ARTKT-1 study biosamples

• good representation of CD8 subsets --the CCR7+, CD28 null CD57+ and the CCR7- CD45RA+ subsets - and orientation in the Introduction as to why these sub-populations.

• good command of the transcriptomic methods

• limitation section is an honest assessment, including the comments on the methodological pathway in biomarker research

Inconsistencies in the internal congruence of the work:

• Sometimes cells are called T cells and sometimes CD8 cells eg in abstract CD28 null CD57+ T cells in one place and CD8+ T cells in another

• Convention of using the / in the string describing the CD8 cells is confusing because

o Applied inconsistently

o Reader has to work hard to decipher in the section about ratios of the different cell populations, see results starting line 274 where cell proportions are reported

• line 440 CD8 subset described as CD57+CD28nullCD8+ T cells and everywhere else the more common convention of CD28nullCD57+CD8+ T cells in used. Please edit

I have the following queries:

Q1 what was the selection process of samples ie n=32 normals + n=50 TCMR + n=39 LTGS = 121 total from the banked biosamples of the ARTKT-1 study?

Q2: are the patients of this study unique or have they been reported in other studies/publications?

Q3: please confirm which groups have kidney tissue as well as peripheral blood ie were the LTGS biopsied (table 1 indicates not)?

Q4: what were the indications for the n=91 biopsies in the normal biopsy control group in table 1?

Q5: there are 4 transplant centres and 3 Institutional Review Boards. Which Board has oversight of which 2 transplanting centres?

Q6: table 1 shows significant differences between the 3 study groups. Suggestion: brief commentary acknowledging this and does it have an impact on results in anyway ie older age group in LTGS?

Q7: please confirm that ARTKT-1 was used only to identify participants and access kidney tissue. Participants were then approached for their peripheral blood. (Methods describes flow cytometry on blood within a few hours of collection). If this is so, what is the time interval between deposition of biosamples in ARTKT-1 and the sampling of the peripheral blood?

Q8: micro-array and flow cytometric data were correlated for n=108. Please confirm these are discrete from the n=153 participants in the ARTKT-1 study reported in reference 8.

Q9: please confirm n=108 are a subset of the n=121 reported in table 1.

Q10: if so, why was the n=121 reduced to n=108? Which of the 3 groups was reduced and by how much?

Q11: similarly, expression data were matched to cell-phenotype data in n=101 samples. Please account for the reduced sample set, including which groups were reduced by how much and why

Q12: is the control group in the microarray studies (n=3 healthy volunteers, line 200) a subset of the control group in table 1?

Q13: Line 323 describes these as the same donors. Same donors as which group?

Q14: please confirm cells in the microarray studies are pooled as opposed to single cell RNA sequencing.

Q15: the text of line 279 does not align with Figures 2C-2D which it references where the data for the TCMR group have a lower mean. It appears the figures are reporting the inverse of the text. If this is so, suggest align the text and figures.

Q16: point of clarification -- is table 3 CCR7+ CD8+ T cells as described in the text in line 338 or CCR7-CD8+ T cells as described in the legend of the table, line 397?

Q17: similarly, in table 4, line 341 reads as the comparator group is CCR7+ CD8+ cells vs the table legend, line 423 has CCR7-CD8+ cells as the comparator group

Q18: I found the text describing the results in tables 3 and 4 confusing -- lines 335 to 341. Table 3 reports on 7 genes, of which 5 appear to move in the same direction as the comparator but the text in line 336 suggests otherwise. What am I missing here?

Q19: Similarly, in table 4, where the text suggests 25 genes up-regulated in the ex vivo experiments are down regulated in the in vivo experiments -- lines 338 to 341 -- but table 4 shows scores in the same direction

Q20: line 442 highlights the sections of Figure 4 are not contiguous ie panel D is after panel D and not panel C. Please edit

Q21: line 482 has significance in it twice. Please edit

Reviewer \#2: This reviewer appreciated reading this manuscript and the efforts the authors undertook to conduct this study. Chung et al. give insights into there experience of CD8 T-cell subsets monitoring among kidney transplant recipients to predict the development of TCMR.

However, this manuscripts includes some major issues that highly dampen the enthusiasm.

\- Heterogeneity of the study groups with respect to import baseline characteristics, that my have confounded the presented findings:

o Time of sampling posttransplantation: while the mean time posttransplantation in the normal control group was 6.6 months, the mean time in the TCMR group was 18.0 months. The expected impact of induction immunosuppression, high-dose initial maintenance immunosuppression, and ABO desensitization therefore may have contributed to the observed findings. Particularly the impact of thymoglobuline on effector memory T-cells impacts the early posttransplant period. After thymoglobuline induction effector memory T cells are expected to recover to pretransplant values by 3 to 6 months posttransplantation.

o One wounders why the mean time to TCMR was 18 months. Where these patients experiencing previous TCMRs and treatment for previous TCMR? The authors should consider including patients with first TCMR and only within the first posttransplant year to account for heterogeneity in the study groups.

o Cyclosporin vs Tacrolimus: while almost all patients in the normal control group were unter tacrolimus, 20% of the patients in the TCMR group were under cyclosporine. The authors should provide and reckon the impact CNI trough levels on their findings.

o More information need to be provided on clinical characteristics with respect to: retansplantation, other solid organ transplantation, previous TCMR, presensitization.

\- The is a remarkable overlap of the presented findings between patients of the normal control group and patients of the TCMR group. Due to the cross-sectional study design (with samples obtained at active TCMR) no conclusions with respect to the predictive value of those biomarkers can be made.

At least in this reviewers point of view, the cross-sectional design, the heterogeneity of the study population and the lack of characterization of donor-specificity of those T-cell responses limit the novelty of the findings and the presented manuscript.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Helen G Healy

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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7 Apr 2020

Dear Prof. Justyna Gołębiewska

Academic Editor, PLOS ONE

Thank you very much for the evaluation of our manuscript. We are returning a revised manuscript which incorporates many of the suggestions made by reviewers. A response to the reviewer's suggestions has been listed one by one, and an index of change has been included. We hope that the comments of the reviewers are adequately addressed in the revised manuscript.

Manuscript number: PONE-D-19-34852

Manuscript title:

Phenotype and molecular signature of CD8+ T cell subsets in T cell- mediated rejections after kidney transplantation

Index of changes

Major changes:

1\. Addition of the information of clinical characteristics with respect to re-transplantation, and other solid transplantation, previous TCMR, pre-sensitization.

2\. Provide a comment on the significant differences between the 3 study groups

3\. Explain about the selection process of samples

4\. Addition of the explanation of ARTKT-1 cohort.

Minor changes

1\. Correction of typos

Sincerely yours,

Byung Ha Chung M.D., Ph.D.,

Associated Professor, department of Internal Medicine

Seoul St. Mary's Hospital, The Catholic University of Korea.

Phone: 82-2258\--6066, Fax: 82-2-536-0323

E-mail: <chungbh@catholic.ac.kr>

Response to Editor's comments

1\. Please provide information on clinical characteristics with respect to: retansplantation, other solid organ transplantation, previous TCMR, pre-sensitization.

→ Thank you for your comments. We added the information about re-transplant, previous TCMR, pre-sensitization in table 1 in the revised manuscript. We did not include any case of other solid organ transplantation, so we added the description "we did not include patient who took any other solid organ transplantation" in the revised manuscript,

2\. Please provide a comment on the significant differences between the 3 study groups

→ Thank you for your comments. We described the significant differences between the 3 study groups as a limitation of this study in the discussion session.

3\. What was the selection process of samples ie n=32 normals + n=50 TCMR + n=39 LTGS = 121 total from the banked biosamples of the ARTKT-1 study?

→ Thank you for your comment. We selected these samples just according to availability of PBMCs samples from the banked biosamples of the ARTKT-1 study. So, we just tried to include all cases whose PBMC samples were available for this study.

4\. What were the indications for the n=91 biopsies in the normal biopsy control group in table 1?

→ The number of normal biopsy was 32 not 91. The indications for normal control was "surveillance biopsy". We included those cases when biopsy finding showed "unremarkable findings" without any evidence of acute rejection, BK virus nephropathy or any pathologic findings.

5\. Please confirm that ARTKT-1 was used only to identify participants and access kidney tissue. Participants were then approached for their peripheral blood. (Methods describes flow cytometry on blood within a few hours of collection). If this is so, what is the time interval between deposition of biosamples in ARTKT-1 and the sampling of the peripheral blood?

→ Thank you for your comments. We can confirm that ARTKT-1 was used only to identify particitipants and access kidney tissue. We added following sentence in the revised manuscript. "ARTKT-1 was used only to identify participants and access kidney tissue."

There is some error in the description for flowcytometry. At first, cells were frozen immediately after collected at the time of allograft biopsy, and were transported to our center for flowcytometric analysis. So we omitted the sentences "In the samples used for the ex vivo study, we did flow cytometry analysis within a few hours after collection of peripheral blood." in the revised manuscript. Deposition of biosamples in ARTKT-1 was done within 1 hour after the sampling of peripheral blood. We added this description as well.

6\. The number of participants/analyzed samples differs for various analyses - Please account for the reduced sample set, including which groups were reduced by how much and why.

→ Thank you for your comments. The patients (n=109) used to investigate the association between phenotype and transcript is an independent group to the patients group (n=121) used in the analysis in this study. The PBMC samples of those 109 patients were used for previous study (Immune Netw. 2018;18(5):e36), hence additional samples were not available any more for this study any more. We just used those data to show the association between immune cell phenotype and transcript in peripheral blood of kidney transplant recipients.

Response to reviewers' comments:

Reviewer \#1

Reviewer \#1: Research pursues one of the universal aims of kidney transplantation: cells in the peripheral blood tell us the pathobiological processes in the allograft.

Strengths of the research

• access to samples - over 10 years clinical follow up, sound control groups, access to the ARTKT-1 study biosamples

• good representation of CD8 subsets -the CCR7+, CD28 null CD57+ and the CCR7- CD45RA+ subsets - and orientation in the Introduction as to why these sub-populations.

• good command of the transcriptomic methods

• limitation section is an honest assessment, including the comments on the methodological pathway in biomarker research

Inconsistencies in the internal congruence of the work:

• Sometimes cells are called T cells and sometimes CD8 cells eg in abstract CD28 null CD57+ T cells in one place and CD8+ T cells in another

→ Thank you for your comments. We used only CD8+ T cells around the whole manuscript in the revised manuscript.

• Convention of using the / in the string describing the CD8 cells is confusing because

o Applied inconsistently

o Reader has to work hard to decipher in the section about ratios of the different cell populations, see results starting line 274 where cell proportions are reported

→ Thank you for your comment We omitted "/" in the revised manuscript to avoid confusing.

• line 440 CD8 subset described as CD57+CD28nullCD8+ T cells and everywhere else the more common convention of CD28nullCD57+CD8+ T cells in used. Please edit

→ Thank you for your comments. We edited all terms of immune cells in the revised manuscript.

I have the following queries:

Q1 what was the selection process of samples ie n=32 normals + n=50 TCMR + n=39 LTGS = 121 total from the banked biosamples of the ARTKT-1 study?

→ Thank you for your comment. We selected these samples just according to availability of PBMCs samples from the banked biosamples of the ARTKT-1 study. So, we just tried to include all cases whose PBMC samples were available for this study.

Q2: are the patients of this study unique or have they been reported in other studies/publications?

→ Thank you for your comment. The data using biosamples included in the ARTKT-1 study have been reported in other studies. (J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jun 15;1118-1119:157-163. Sci Rep. 2019 Feb 12;9(1):1854. PLoS One. 2018 Sep 18;13(9):e0204204. PLoS One. 2018 Jul 16;13(7):e0200631, PLoS One. 2017 Dec 21;12(12):e0190068.)

Q3: please confirm which groups have kidney tissue as well as peripheral blood ie were the LTGS biopsied (table 1 indicates not)?

→ We can confirm that ARTKT-1 was used only to identify particitipants and access kidney tissue. We added following sentence in the revised manuscript.

"ARTKT-1 was used only to identify participants and access kidney tissue."

Q4: what were the indications for the n=91 biopsies in the normal biopsy control group in table 1?

→ The number of normal biopsy was 32 not 91. The indications for normal control was "surveillance biopsy". We included those cases when biopsy finding showed "unremarkable findings" without any evidence of acute rejection, BK virus nephropathy or any pathologic findings.

Q5: there are 4 transplant centres and 3 Institutional Review Boards. Which Board has oversight of which 2 transplanting centres?

→ IRB for kyoung-hee neomedical center has oversight both Kyoung Hee University Hospital at Gangdong, Kyung Hee University Hospital. We corrected it accordingly in the revised manuscript.

Q6: table 1 shows significant differences between the 3 study groups. Suggestion: brief commentary acknowledging this and does it have an impact on results in anyway ie older age group in LTGS?

→ Thank you for your comments. It is possible that the significant difference between three groups can have impact on results. So, we mentioned the significant heterogeneity is the limitation of this study in the revised manuscript.

Q7: please confirm that ARTKT-1 was used only to identify participants and access kidney tissue. Participants were then approached for their peripheral blood. (Methods describes flow cytometry on blood within a few hours of collection). If this is so, what is the time interval between deposition of biosamples in ARTKT-1 and the sampling of the peripheral blood?

→ Thank you for your comments. We can confirm that ARTKT-1 was used only to identify particitipants and access kidney tissue. We added following sentence in the revised manuscript. "ARTKT-1 was used only to identify participants and access kidney tissue."

There is some error in the description for flowcytometry. At first, cells were frozen immediately after collected at the time of allograft biopsy, and were transported to our center for flowcytometric analysis. So we omitted the sentences "In the samples used for the ex vivo study, we did flow cytometry analysis within a few hours after collection of peripheral blood." in the revised manuscript. Deposition of biosamples in ARTKT-1 was done within 1 hour after the sampling of peripheral blood. We added this description as well.

Q8: micro-array and flow cytometric data were correlated for n=108. Please confirm these are discrete from the n=153 participants in the ARTKT-1 study reported in reference 18.

→ Thank you for your comments. These 108 cases are a subset of n=153 participants in the ARTKT-1 study in reference 18 (Immune Netw. 2018;18(5):e36). As we described in the manuscript, "we used microarray and flowcytometry data of 108 KTRs in whom the data for CCR7+CD8+ T, CCR7-CD45RA+CD8+ T, and CD28nullCD57+CD8+ T cells were available."

In other words, both flowcytometric and microarray data were available in those 108 patients out of 153 participants..

Q9: please confirm n=108 are a subset of the n=121 reported in table 1.

→ The patients (n=109) used to investigate the association between phenotype and transcript is an independent group to the patients group (n=121) used in the analysis in this study. The PBMC samples of those 109 patients were used for previous study (Immune Netw. 2018;18(5):e36), hence additional samples were not available any more for this study any more. We just used those data to show the association between immune cell phenotype and transcript in peripheral blood of kidney transplant recipients.

Q10: if so, why was the n=121 reduced to n=108? Which of the 3 groups was reduced and by how much?

→ As we mentioned above (for Q9), The patients (n=108) used to investigate the association between phenotype and transcript is independent group to the patients group (n=121) used in the analysis in this study.

Q11: similarly, expression data were matched to cell-phenotype data in n=101 samples. Please account for the reduced sample set, including which groups were reduced by how much and why

→ As we mentioned above (for Q9), The patients (n=108) used to investigate the association between phenotype and transcript is independent group to the patients group (n=121) used in the analysis in this study.

Q12: is the control group in the microarray studies (n=3 healthy volunteers, line 200) a subset of the control group in table 1?

→No, we used blood samples from healthy volunteers. They were kidney transplant recipients. They were just healthy volunteers and so not were included in table 1

Q13: Line 323 describes these as the same donors. Same donors as which group?

→ Same donor means that we collected PBMCs for the microarray analysis on CCR7+CD8+ T cells and also CCR7-CD8+ T cells from same donor.

Q14: please confirm cells in the microarray studies are pooled as opposed to single cell RNA sequencing.

→ Yes, we pooled cells for microarray as opposed to single cell RNA sequencing. We added this description in the revised manuscript.

Q15: the text of line 279 does not align with Figures 2C-2D which it references where the data for the TCMR group have a lower mean. It appears the figures are reporting the inverse of the text. If this is so, suggest align the text and figures.

→ Thank you for your comments. We revised it accordingly as follows

"it was significantly lower in the TCMR group than in the NC or LTGS group."

Q16: point of clarification - is table 3 CCR7+ CD8+ T cells as described in the text in line 338 or CCR7-CD8+ T cells as described in the legend of the table, line 397?

→ Thank you for your comments. It was error. We corrected it to CCR7+CD8+ T

Q17: similarly, in table 4, line 341 reads as the comparator group is CCR7+ CD8+ cells vs the table legend, line 423 has CCR7-CD8+ cells as the comparator group

→ Thank you for your comments. It was error. We corrected it to CCR7+CD8+ T

Q18: I found the text describing the results in tables 3 and 4 confusing - lines 335 to 341. Table 3 reports on 7 genes, of which 5 appear to move in the same direction as the comparator but the text in line 336 suggests otherwise. What am I missing here?

→ Thank you for your comments.

"Out of the eight up-regulated genes along with the ex vivo CCR7-CD45+CD8+ T cells\~"

Above eight up-regulated genes are presented in Table S2, and out of them, "five genes were included in the down-expressed genes on in vitro CCR7+CD8+ T cells" as shown in table 3. We indicated 'Table S2' in the revised manuscript to avoid confusion.

Q19: Similarly, in table 4, where the text suggests 25 genes up-regulated in the ex vivo experiments are down regulated in the in vivo experiments - lines 338 to 341 - but table 4 shows scores in the same direction

→ Thank you for your comments. Similarly, we indicated 'Table S3' in the revised manuscript as follows.

"25 out of 124 up-regulated genes and 10 out of 19 down-regulated genes along with ex vivo CD28nullCD57+CD8+ T cells (Table S3) were included in the down-regulated or up-regulated genes on in vitro CCR7+CD8+ T cells, respectively, as shown in Table 4.

Q20: line 442 highlights the sections of Figure 4 are not contiguous ie panel D is after panel D and not panel C. Please edit

→ This legend is confusing, so we revised it as follows

"Combination of the ratio between CCR7+CD8+ T vs CD28nullCD57+CD8+ T and the ratio between CCR7+CD8+ T vs CD45RA+CCR7-CD8+ T"

Q21: line 482 has significance in it twice. Please edit

→ Thank you for your comment, We edit it

Reviewer \#2: This reviewer appreciated reading this manuscript and the efforts the authors undertook to conduct this study. Chung et al. give insights into there experience of CD8 T-cell subsets monitoring among kidney transplant recipients to predict the development of TCMR.

However, this manuscripts includes some major issues that highly dampen the enthusiasm.

\- Heterogeneity of the study groups with respect to import baseline characteristics, that may have confounded the presented findings:

→ Thank you for your comments. We described the significant differences between the 3 study groups as a limitation of this study in the discussion session.

o Time of sampling posttransplantation: while the mean time posttransplantation in the normal control group was 6.6 months, the mean time in the TCMR group was 18.0 months. The expected impact of induction immunosuppression, high-dose initial maintenance immunosuppression, and ABO desensitization therefore may have contributed to the observed findings. Particularly the impact of thymoglobuline on effector memory T-cells impacts the early posttransplant period. After thymoglobuline induction effector memory T cells are expected to recover to pretransplant values by 3 to 6 months posttransplantation.

→ Thank you for your comments. We described above comments as limitation of this study in the revised manuscript.

o One wounders why the mean time to TCMR was 18 months. Where these patients experiencing previous TCMRs and treatment for previous TCMR? The authors should consider including patients with first TCMR and only within the first posttransplant year to account for heterogeneity in the study groups.

→ Thank you for your comments. We excluded 33 cases who suffered previous TCMR or late TCMR (\> 1 post-transplant year) in TCMR group, hence we performed additional analysis only for the first TCMR cases occurred within 1 post-transplant year. But, as shown in the below figure, the results showed very similar pattern to that presented in the original manuscript.

o Cyclosporin vs Tacrolimus: while almost all patients in the normal control group were under tacrolimus, 20% of the patients in the TCMR group were under cyclosporine. The authors should provide and reckon the impact CNI trough levels on their findings.

→ Thank you for your comments, We added above contents as limitation of this study in the revised manuscript.

o More information need to be provided on clinical characteristics with respect to: retansplantation, other solid organ transplantation, previous TCMR, presensitization.

→ Thank you for your comments. We added the information about re-transplant, previous TCMR, pre-sensitization in table 1 in the revised manuscript. We did not include any case of other solid organ transplantation, so we added the description "we did not include patient who took any other solid organ transplantation" in the revised manuscript,

\- The is a remarkable overlap of the presented findings between patients of the normal control group and patients of the TCMR group. Due to the cross-sectional study design (with samples obtained at active TCMR) no conclusions with respect to the predictive value of those biomarkers can be made.

→ Thank you for your comments and we absolutely agree with your opinion. Therefore, we described the limitation of this study as follows ; "We analyzed samples taken from a cross-sectional cohort; hence we did not investigate the dynamic changing pattern of each cell type. It will be necessary to observe the change of each cell type in a prospective cohort."

At least in this reviewers point of view, the cross-sectional design, the heterogeneity of the study population and the lack of characterization of donor-specificity of those T-cell responses limit the novelty of the findings and the presented manuscript.

→ Thank you for your important comments. We added your comments as the limitation of this study in the revised manuscript. "Lastly, three groups showed significant heterogeneity in terms of clinical characteristics, and also we did not show donor-specificity of T cell responses, which can limit the novelty of this study."
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#3: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?
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4\. Have the authors made all data underlying the findings in their manuscript fully available?
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one comment
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